Qian Zhao

USPTO Granted Patents = 62 (Patent Applications = 11)

CIPO Patents = 11 (Patent Applications = 12)

EPO Patents = 20 (Patent Applications = 23)

Average Co-Inventor Count = 7.7

ph-index = 12

Forward Citations = 455(Granted Patents)

DiyaCoin

= 0.16

Inventors with similar research interests:

Location History:

Superior, CO (US) (2008 - 2020)
Louisville, CA (US) (2020)
El Cerrito, CA (US) (2014 - 2021)
Boulder, CO (US) (2013 - 2024)
Louisville, CO (US) (2014 - 2024)

Company Filing History:

Mirati Therapeutics, Inc.

patents

4. 2 out of 919

Gilead Sciences, Inc.

where one patent can have more than one assignee

Years Active: 2008-2025

where 'Filed Patents' based on already Granted Patents

62 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12338220 - Antiviral pyrazolopiridinone compounds (2025-06-24),

2. 12171739 - N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases (2024-12-24),

3. 12071441 - 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1',2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza (2024-08-27),

4. 11964989 - KRas G12D inhibitors (2024-04-23),

5. 11912715 - Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections (2024-02-27),

6. 11780835 - Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases (2023-10-10),

7. 11667613 - Antiviral pyrazolopyridinone compounds (2023-06-06),

8. 11629149 - 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1',2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza (2023-04-18),

9. 11453683 - KRas G12D inhibitors (2022-09-27),

10. 11453677 - Tricyclic compounds useful to treat orthomyxovirus infections (2022-09-27),

11. 11174273 - Quinazoline analogs as receptor tyrosine kinase inhibitors (2021-11-16),

12. 11104676 - Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases (2021-08-31),

13. 11098051 - Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections (2021-08-24),

14. 11091486 - Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof (2021-08-17),

15. 11072610 - Antiviral pyridopyrazinedione compounds (2021-07-27),

Title: Spotlight on Inventor Qian Zhao: Pioneering Innovations in Biopharmaceuticals

Introduction:

In the realm of biopharmaceutical innovations, one name stands out for his prolific contributions - Qian Zhao. Based in Superior, CO (US), Qian Zhao is a renowned inventor with an impressive portfolio of 59 patents to his name. His groundbreaking work in developing compounds targeting oncogenic mutations and orthomyxovirus infections has earned him recognition in the scientific community.

Latest Patents:

Qian Zhao's latest patents showcase his ingenuity and commitment to advancing the field of biopharmaceuticals. One notable innovation is the development of KRas G12D inhibitors - compounds designed to inhibit the activity of KRas G12D, with a focus on treating cancer. These compounds, represented by Formula (I) or its salt, offer promising prospects in cancer therapy. Additionally, Qian Zhao has pioneered fused tricyclic pyridazinone compounds for treating orthomyxovirus infections, particularly influenza, demonstrating his versatility in addressing diverse medical challenges.

Career Highlights:

Throughout his career, Qian Zhao has made significant contributions to the biopharmaceutical industry. Notably, he has been associated with esteemed organizations such as Array Biopharma Inc. and Novartis AG, where his expertise has been instrumental in driving innovation and scientific discovery. Qian Zhao's pioneering research has paved the way for novel treatments and therapeutic strategies in the realm of precision medicine.

Collaborations:

In his quest for scientific excellence, Qian Zhao has collaborated with accomplished professionals in the field. Notable among his coworkers are Joseph P Lyssikatos and Eli M Wallace, who have worked alongside him in realizing innovative solutions for complex biomedical challenges. Through synergistic collaborations, Qian Zhao has fostered a culture of innovation and knowledge-sharing, resulting in impactful advancements in biopharmaceutical research.

Conclusion:

Inventor Qian Zhao's remarkable journey is characterized by a relentless pursuit of innovation and a steadfast dedication to transforming the landscape of biopharmaceuticals. His pioneering patents, career highlights, and collaborative efforts underscore his standing as a visionary inventor shaping the future of medical interventions. With a proven track record of excellence, Qian Zhao continues to inspire and lead the way in pioneering groundbreaking solutions for unmet medical needs.

This text is generated by artificial intelligence and may not be accurate.